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Peritoneal ﬁbrosis is one of the major complications occurring in long-term peri-
toneal dialysis patients as a result of injury. Peritoneal ﬁbrosis is characterized by
submesothelial thickening and ﬁbrosis which is associated with a decline in peri-
toneal membrane function. The myoﬁbroblast has been identiﬁed as the key player
involved in the development and progression of peritoneal ﬁbrosis. Activation of the
myoﬁbroblast is correlated with expansion of the extracellular matrix and changes
in peritoneal membrane integrity. Over the years, epithelial to mesenchymal tran-
sition (EMT) has been accepted as the predominant source of the myoﬁbroblast.
Peritoneal mesothelial cells have been described to undergo EMT in response to
injury. Several animal and in vitro studies support the role of EMT in peritoneal
ﬁbrosis; however, emerging evidence from genetic fate-mapping studies has
demonstrated that myoﬁbroblasts may be arising from resident ﬁbroblasts and
pericytes/perivascular ﬁbroblasts. In this review, we will discuss hypotheses
currently surrounding the origin of the myoﬁbroblast and highlight the experi-
mental systems predominantly being used to investigate this.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Peritoneal dialysis (PD) is a widely used renal replacement
therapy for patients with end-stage renal disease [1,2]. The
healthy peritoneum is a semipermeable membrane consisting
of a superﬁcial mesothelial layer, a basement membrane, and a
thin submesothelial zone (Fig. 1A) [3]. Long-term exposure to
bioincompatible dialysis solutions, uremia [4], and intermittent
peritonitis [5] leads to a low-grade chronic inﬂammation,
triggering a reparative response. This response normally pro-
vides restoration of tissue structure with minimal loss of
function. However, this reparative mechanism may becomerology, Department of
s Hospital, 50 Charlton
da.
getts).
ty of Nephrology. Published b
/4.0/).dysregulated. This results in tissue ﬁbrosis with deposition of
extracellular matrix (ECM), angiogenesis, and eventual mem-
brane failure (Fig. 1B). The appearance of myoﬁbroblasts in the
submesothelial tissue is a critical component of peritoneal
membrane ﬁbrosis and angiogenesis [5].The myoﬁbroblast in ﬁbrosis
The myoﬁbroblast is a specialized contractile cell that ex-
presses both ﬁbroblast and smooth muscle cellelike charac-
teristics [6]. Myoﬁbroblasts are motile cells and therefore
possess stress ﬁbers and rufﬂed cell membranes due to changes
in the actin cytoskeleton [7]. Stress ﬁbers are composed of
bundles of actin microﬁlaments and contractile proteins. Actin
microﬁlaments terminate at the cell surface in a specialized
adhesion complex termed the ﬁbronexus that becomes linked
to extracellular ﬁbronectin ﬁbrils [7]. This creates ay Elsevier. This is an open access article under the CC BY-NC-ND license
Figure 1. Histology of the peritoneal membrane. (A) Healthy mouse peritoneum taken from the anterior adbominal wall consists of superﬁcial meso-
thelial layer and a thin submesothelial zone. (B) Exposure to an adenovirus expressing transforming growth factor beta results in submesothelial thickening,
angiogenesis, and increased cell number in the peritoneum.
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force from stress ﬁbers to the ECM. Similarly, mechanical sig-
nals from the extracellular environment can activate intracel-
lular signaling pathways [8]. Expression of alpha smooth
muscle actin (a-SMA) is a key marker that distinguishes the
myoﬁbroblast from the ﬁbroblast [9]. Although the function of
the myoﬁbroblast has not fully been elucidated, the myoﬁbro-
blast has mostly been studied for its role in wound healing and
its presence during pathological conditions such as ﬁbrosis.
Originally, myoﬁbroblasts were observed in granulation tissue
of healing wounds. They were observed to produce the con-
tractile force required during wound contraction. More
recently, several studies have identiﬁed the myoﬁbroblast as an
important element in the production of ECM and progression of
ﬁbrosis [7,10].
In a healthy environment, stromal cells including ﬁbroblasts
and perivascular cells remain quiescent, producing little ECM
and few actin interactions between cells and cell to matrix [8].
In response to injury, myoﬁbroblasts accumulate at the site of
injury where they produce ECM in response to cytokines from
local cells [6,8]. Transforming growth factor beta (TGF-b) is a
key cytokine that regulates expression of a-SMA and type 1
collagen in the myoﬁbroblast [9,11]. Moreover, the differentia-
tion process of the myoﬁbroblast is largely regulated by TGF-b.
In addition to TGF-b, myoﬁbroblasts are also stimulated by
changes in the mechanical microenvironment and high extra-
cellular stress [7,8]. During normal conditions, the ECM main-
tains its cross-linked structure; however, tissue injury results in
remodeling of the ECM and changes in the mechanical envi-
ronment. In response to this change in ECM structure and
TGF-b signaling, precursor cells begin to acquire contractile
stress ﬁbers [7]. During this time, myoﬁbroblasts express some
features that are similar to ﬁbroblasts such as actin stress ﬁbers.
This transitional cell has been characterized as the proto-
myoﬁbroblast [8,12]. The protomyoﬁbroblast begins to acquire
more contractile activity with the expression of a-SMA in the
stress ﬁbers and can now be characterized as a myoﬁbroblast.
ECM stiffness is one promoter of myoﬁbroblast maturation
[12,13]. During the ﬁnal stages of wound healing, the ECM
regains its normal structure and the myoﬁbroblasts undergo
apoptosis [8,12].
The last component of the wound-healing response involves
replacement of injured cells with new cells and resolution of
scar tissue to preserve functional and structural integrity of theorgan [14]. However, this is not always the case depending on
the type and duration of injury as well as the severity of
damage. Often, chronic injury may result in the inability to
replace scar tissue with functional tissue resulting in irrevers-
ible ﬁbrosis [14]. Therefore, ﬁbrosis is largely characterized as
accumulation of ECM including collagen, proteoglycans, and
ﬁbronectin [10]. The myoﬁbroblast is the primary effector cell
that is activated during this process [10]. Myoﬁbroblast pop-
ulations have been noted in abnormal wound healing in several
vital organs such as the kidney, lung, liver, and heart [11,15,16].
Myoﬁbroblasts have also emerged as the main effector cell
contributing to peritoneal ﬁbrosis. The presence of the myoﬁ-
broblast contributes to the loss of integrity of the peritoneal
membrane in long-term PD patients by inducing collagen
deposition resulting in structural and functional changes in the
peritoneal membrane [17]. In PD patients, the myoﬁbroblast is
dominant in the peritoneal membrane even before ﬁbrosis is
present in contrast to the normal healthy peritoneum [18].
It is challenging to study stromal cells; ﬁbroblasts do not
express any speciﬁc markers resulting in difﬁculties dis-
tinguishing them from other cells [10]. Several studies have
used ﬁbroblast speciﬁc protein (FSP) 1 (also known as S100A4)
as a ﬁbroblast-speciﬁc marker [19]. Recent evidence demon-
strates FSP1 is not speciﬁc to ﬁbroblasts and is also expressed in
other cells such as monocytes [40]. Myoﬁbroblast expression of
a-SMA is increasingly being used as the method of identifying
the myoﬁbroblast. However, this marker still presents some
challenges as a-SMA is also expressed by other cells of the
mesenchymal lineage such as vascular smooth muscle cells
[10].
Origin of the myoﬁbroblast: current hypotheses
As the myoﬁbroblast is the key effector cell in progression of
ﬁbrosis, it is of scientiﬁc and practical interest to elucidate the
origin of this cell. This is a controversial area of research. In
various research studies, myoﬁbroblasts have been shown to
derive from different cellular sources including resident ﬁbro-
blasts [8,16], epithelial cells via epithelial to mesenchymal
transition (EMT) [20], endothelial cells (endothelial to mesen-
chymal transition) [21], perivascular cells [22], and bone mar-
rowederived cells [19,23]. Interestingly, the original hypothesis
was that myoﬁbroblasts arose from locally residing mesen-
chymal cells such as resident ﬁbroblasts and pericytes/
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wound healing [12,24] (Fig. 2A). This was also supported in
models of ﬁbrosis such as scleroderma [25] and liver and renal
ﬁbrosis [12,26]. However, this view quickly changed as a result
of accumulating evidence in support of conversion of local
epithelial cells via EMT [27] (Fig. 2B). The ﬁrst piece of evidence
comes from studies in vitro where epithelial cells can be
transformed into myoﬁbroblasts by exposing cells to wound-
healing cytokines such as TGF-b [27]. Secondly, evidence from
experimental ﬁbrosis in animal models has provided us with
snapshots of molecular markers of EMT in vivo [28]. Myoﬁ-
broblasts appear in the submesothelial zone in experimental
models of peritoneal ﬁbrosis [17] and have been observed in
biopsy samples in PD patients with peritoneal ﬁbrosis [29]. The
origin of the myoﬁbroblasts in peritoneal membrane injury
remains an area of active research. Early studies, including our
own work, have pointed to EMT as a source of submesothelial
myoﬁbroblasts. More recently, these observations have been
challenged by cell fateetracing experiments [30]. There is also
some experimental evidence that myoﬁbroblasts can originate
from the bone marrow and play a role in peritoneal ﬁbrosis
[19,23].Figure 2. Proposed theories on the origin of the myoﬁbroblast, submesoth
result of exposure to bioincompatible dialysate and intermittent inﬂammatio
mesothelium is not necessary for subsequent myoﬁbroblast accumulation, subm
response. (B) In this model, full EMT occurs with injury inducing mesothelial t
membrane into the submesothelial space and form a subset of the submeso
angiogenesis. (C) In this model, mesothelial transition occurs without migration
growth factors (TGF-b and VEGF) that then drive submesothelial ﬁbrosis and a
EMT, epithelial to mesenchymal transition; TGF-b, transforming growth factorIn vitro and ex vivo evidence for EMT
The study of the origins of the myoﬁbroblast began in vitro
and moved into experimental animal models. Initial evidence
supporting EMT comes from studies in vitro where epithelial
cells have been induced to transform into myoﬁbroblasts dur-
ing conditions of injury [31,32]. This process has been exten-
sively studied in renal ﬁbrosis where primary tubular epithelial
cells exposed to TGF-b undergo EMT [33].
These studies have been fundamental in our understanding
of the EMT process by deﬁning the basic markers used to
characterize EMT and the signaling pathways involved during
this process [28]. EMTcan be considered as a 2-step process, the
primary step being cellular transition followed by invasion into
the interstitial tissue (Fig. 2B) [27]. In vitro studies have outlined
the process of cellular transition, but in standard 2-dimensional
cell culture, cellular invasion has been more difﬁcult to study;
EMT is characterized by the loss of cell adhesion through
downregulation of intercellular adhesion molecules such as E-
cadherin, loss of cell polarity, rearrangement of the cytoskel-
etonwith an increased expression of a-SMA, and acquisition of
migratory behavior (Fig. 2B) [27,28]. During the last stage ofelial ﬁbrosis, and angiogenesis. Peritoneal membrane injury occurs as a
n or infection. (A) Although injury can damage the mesothelial cells, the
esothelial ﬁbrosis, and angiogenesis, which is driven directly by the injury
ransition and transitioned mesothelial cells migrate through the basement
thelial myoﬁbroblasts. These cells then drive submesothelial ﬁbrosis and
(in situ EMT). These transitioned mesothelial cells are an essential source of
ngiogenesis.
beta; VEGF, vascular endothelial growth factor.
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mesenchymal cell can migrate into the interstitial layers and
deposit collagen resulting in ﬁbrosis (Fig. 2B). Metal-
loproteinases (MMPs) are usually thought to be involved in
degradation of the basement membrane and may facilitate
invasion of transitioned cells [27,34].
The EMT cellular program is driven by initiating factors such
as hypoxia, inﬂammation, or growth factors such as TGF-b.
These activate transcriptional regulators such as Snail, Zinc
ﬁnger E-box-binding homeobox, or Twist [35]. These tran-
scriptional regulators then initiate a genetic program that leads
to the EMT phenotype [35].
Studies in vitro have been useful because they can demon-
strate the transitional aspect of EMT by measuring cell move-
ment and combining this with changes in cell phenotype [36].
Matrigel (Corning Life Sciences, Tewksbury, MA) is a common
substrate used to measure cellular invasion, and studies have
used this as a method of measuring cell movement [37].
However, cross-linked, mature basement membrane may not
be susceptible to protease activity as is Matrigel [38]. Similarly,
collagen invasion assays have been used to study cell invasion
against laminin, type I collagen, and type IV collagen. However,
in vivo, the triple-helical structure of collagen is resistant to
proteolytic attack [38]. Therefore, analysis of invasive EMT is
difﬁcult to detect in vivo, and investigators usually have to rely
on recognition of certain markers that reﬂect transition [36].
EMT was ﬁrst demonstrated in the human peritoneum after
dialysis in a landmark paper in 2003 by Ya~nez-Mo et al [39]. An
ex vivo culture of mesothelial cells was developed from peri-
toneal efﬂuent from patients on PD. They found that the cell
morphology could be classiﬁed as epithelioid like or non-
epithelioid like. The epithelioid cells demonstrated the usual
markers such as cytokeratin, E-cadherin, and intercellular
adhesion molecule 1. There was decreased E-cadherin and
cytokeratin expression in cells with a ﬁbroblast phenotype
compared with those with a more epithelioid phenotype [39].
The epithelial markers also declined with time spent on PD. The
gene expression of Snail was increased in transitioning and
ﬁbroblast like cells grown from peritoneal efﬂuent. Conﬂuent
layers of mesothelial cells were also mechanically wounded,
and ﬁbroblastic cells appeared in the layer of migrating cells
near the wound. Cultured cells treated with TGF-b displayed
decreased amounts of E-cadherin and increased levels of Snail.
Biopsy specimen taken from 9 PD patients conﬁrmed the re-
sults from the ex vivo mesothelial culture [39]. These results
have been conﬁrmed by a similar study of mesothelial cells also
derived from peritoneal efﬂuent [2]. These studies strongly
suggest that myoﬁbroblasts may originate from injured meso-
thelial cells undergoing EMT.
These ex vivo cell-based experimental results have been
questioned by recent work in a rodent model of dialysate
exposure [40]. Cho et al [40] found that the evaluation of EMT
markers in the cells grown from the peritoneum of rats treated
with PD solutions did not correlate well with the EMTobserved
in the peritoneal tissues. Whether these results in a rat model
can be applied to patients on PD is still an open question.
Animal models to study peritoneal membrane injury
Experimental animal models can recreate aspects of a
pathophysiological condition and can thus help to identify
mechanisms of disease and identify targets for therapeuticintervention. The extent to which an animal model of human
disease actually simulates the disease state is always open to
criticism [41].
Different animal models have been developed to study the
underlying challenges in PD including viability of the peritoneal
membrane and biocompatibility of dialysis solutions [42].
Experimental animal models give us the ability to study
mechanisms underlying peritoneal membrane injury and could
lead to improvements in current techniques. Historically, in-
vestigators have used rat or rabbit to model PD, generating
acute and chronic models of PD. In a standard acute model of
PD, ﬂuid is infused by intraperitoneal injection or a temporary
catheter into the peritoneal cavity in mice, rats, rabbit, and
sheep [43,44]. This model has been important in understanding
properties of solute transport across the peritoneal membrane,
changes in the interstitial matrix, and changes in attachment
andmorphology of mesothelial cells during injury [45e47]. The
chronic infusion model of PD uses a peritoneal catheter
implanted into rodents which then receive a daily or twice
daily infusion of dialysis ﬂuid for a span of 4e20 weeks [48].
Although this model closely mimics the progression of perito-
neal membrane injury, the indwelling catheter has been shown
to amplify the inﬂammatory response via a foreign body re-
action [49].
The model used extensively in our laboratory and others
involves gene transfer of TGF-b into the rodent peritoneum
[50]. TGF-b is one of the major mediators of peritoneal ﬁbrosis
and angiogenesis and can be delivered to the peritoneum to
model this condition. Adenovirus-mediated gene transfer of
TGF-b has been used to model peritoneal ﬁbrosis in mice [50]
and rats [51]. This model has demonstrated changes in the
functionality and structure of the peritoneum similar to what is
seen in patients on long-term PD. We also have a helper-
dependent adenovirus expressing TGF-b to induce prolonged
expression of the transgene, and this resulted in changes in the
peritoneal structure as observed in encapsulated peritoneal
sclerosis (EPS) [52]. The helper-dependent adenovirus allows
for longer duration and lower expression of transgene with an
attenuated immune response [52].
EPS is a rare disease that occurs in a small minority of PD
patients [52]. Peritoneal ﬁbrosis may be an underlying factor in
the development of EPS, and therefore, the study of EPS can
also provide clues to understanding peritoneal ﬁbrosis. One of
the most commonly used agents to model EPS in animals is
chlorhexidine gluconate [53]. Chlorhexidine was initially used
as a topical antiseptic agent to prevent peritonitis but became
associated with an increased risk of EPS and is now used as an
experimental model of EPS. Daily intraperitoneal injections of
chlorhexidine gluconate can induce peritoneal ﬁbrosis and
angiogenesis in mice and rats [54].
Animal models and EMT
Several animal models of peritoneal membrane injury have
been generated which support the hypothesis that the
epithelium is a source of myoﬁbroblasts. Supported by exten-
sive in vitro data for EMT, researchers have studied common
peritoneal membrane injury models to conﬁrm EMT in vivo
[2,17]. The identiﬁcation of in vivo EMT involves use of surro-
gate markers to identify changes in expression of epithelial
markers, cell-to-cell adhesion molecules, cytoskeletal changes,
and altered regulation of transcription factors associated with
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used to identify EMT include loss of epithelial markers
including E-cadherin and cytokeratin and gain of mesenchymal
markers such as a-SMA and Snail [55]. The most common
method that has been used to provide better visualization of
the EMT process is immunoﬂuorescence analysis of epithelial
and mesenchymal markers [28]. Cells undergoing transition
can then be identiﬁed by analyzing the co-localization of both
epithelial and mesenchymal markers in cells in the peritoneal
membrane [55]. However, these studies have received some
criticism as static markers of EMT are commonly used. Changes
in these markers may not be representative of EMT as EMT is a
more transitory process [28]. Detecting EMT in vivo has pre-
sented several limitations. As mentioned previously, there are
no speciﬁc markers for myoﬁbroblasts, so immunohistochem-
istry is confusing because of nonspeciﬁcity [55]. EMT is a
reversible process, so there may be stages where cells revert to
their parental phenotype and lose their mesenchymal charac-
teristics [55]. There are also more advanced stages where
epithelial cell characteristics are lost completely. Therefore, the
detection of transitioning cells critically depends on the timing
of detection after peritoneal membrane injury [55]. Detection
of intermediate stages of EMT in injured tissue is a simple
method that has been used in the past to identify transitioning
cells in vivo [55]. Intermediate stages of EMT are characterized
by cells expressing epithelial characteristics such as cytokeratin
and E-cadherin but have also acquired mesenchymal markers
such as a-SMA. Therefore, these cells co-express epithelial and
mesenchymal features at the same time [20] (Fig. 3).
Aroeira et al [2] used these immunohistologic methods to
identify EMT in vivo using an animal model of exposure to
glucose-based PD ﬂuids to induce peritoneal ﬁbrosis and
angiogenesis over a period of 5 weeks. This exposure was
accompanied by a failure in ultraﬁltration. After 2 weeks of PD
ﬂuid exposure, there was a loss of mesothelial cells from the
peritoneum. This closely mimics the structural changes that
occur in patients on PD [2]. Immunoﬂuorescence staining for
both an epithelial marker, cytokeratin, and the myoﬁbroblastFigure 3. EMT demonstrated by immunoﬂuorescent labeling of the epithe
Mouse peritoneum treated with control adenovirus (AdDL) does not display an
Treatment of mouse peritoneumwith AdTGF-b results in dual-labeled cells co-ex
arrows). Some cells continue expressing cytokeratin and do not express a-SMA
a-SMA, alpha smooth muscle actin; EMT, epithelial to mesenchymal transitionmarker, a-SMA, was used to identify mesothelial cells and
myoﬁbroblasts, respectively. Dual-labeled cells expressing both
cytokeratin and a-SMA were considered cells undergoing EMT
in the intermediate stages. This analysis revealed that the loss
of mesothelial cells from the peritoneal membrane surface
coincided with the appearance of cells labeled with cytokeratin
and a-SMA in the submesothelium [2]. We have also examined
the process of EMT by combining analysis of EMT-related genes
and proteins along with immunoﬂuorescence staining for EMT
markers in our model of adenovirus-mediated TGF-b gene
delivery (Fig. 3). TGF-b induces peritoneal ﬁbrosis and angio-
genesis in the rodent peritoneum, creating a robust model of
peritoneal membrane injury [17]. Rat peritoneum exposed to
adenovirus expressing TGF-b exhibited increased sub-
mesothelial thickness and angiogenesis. We observed an early
increase in expression of Snail, a-SMA, MMP-2, and type I
collagen. Laminin staining revealed a disruption of the base-
ment membrane at an early time point. Dual staining revealed
cells expressing both epithelial and myoﬁbroblast characteris-
tics in the submesothelial layer [17]. In this study, along with
other studies done in vivo, submesothelial a-SMA-positive
myoﬁbroblasts without epithelial markings are of an unknown
origin. They may be fully transformed epithelial cells, trans-
formed ﬁbroblasts, or other cell types recruited locally or from
the circulation. Therefore, these experiments suggest that at
least some myoﬁbroblasts in the submesothelial space may
come from mesothelial cell conversion and support the notion
of EMT-derived myoﬁbroblasts.
The use of immunoﬂuorescence labeling of epithelial and
myoﬁbroblast markers to identify cells undergoing EMT has
been criticized. This provides only a static picture of the cellular
response to injury, and we have shown that this picture looks
very different depending on the point of time in the injury
response [33,45]. Furthermore, there are criticisms of immu-
noﬂuorescence studies including the nonspeciﬁcity of anti-
bodies used and image-processing artifacts. Different models of
peritoneal injury may yield different temporal patterns of
damage and may thus make detection of EMT challenging. Forlial marker, cytokeratin, and the mesenchymal marker, a-SMA. (AeC)
y dual-labeled cells and displays epithelial cells only (thin arrows). (DeF)
pressing epithelial (cytokeratin) and mesenchymal markers (a-SMA) (thick
(thin arrows).
; TGF-b, transforming growth factor beta.
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TGF-b yields a fairly rapid ﬁbrogenic response, whereas daily
exposure toPDﬂuidswill lead toamoregradual onsetofﬁbrosis,
and it will likely be more difﬁcult to detect EMT using dual
immunoﬂuorescence studies. Finally, different animal strains
may have very different response to ﬁbrogenic stimuli [35].
We have quantiﬁed the EMT response and ﬁnd that very few
cells express both mesenchymal and epithelial markers in the
peritoneum after injury. In general, we ﬁnd only 1e2 cells per
high power ﬁeld to be dual labeled [50,56]. This could indicate
that EMT is a rare event in peritoneal ﬁbrosis or that our
“snapshot” of peritoneal membrane injury captures only those
cells in the process of transition, not those cells fully transi-
tioned to a myoﬁbroblast phenotype.
Fate-tracing experiments and evidence refuting EMT in
peritoneal ﬁbrosis
An alternate method of visualizing the origin of cells in a
complex injury response system has been developed using
inducible genetic fate mapping. Emerging evidence from these
studies sheds more light on the origin of the myoﬁbroblast in
tissue injury and throws into question the dominant role of
EMT in the appearance of submesothelial myoﬁbroblasts. Ge-
netic fate mapping is a technique that allows researchers to
detect the origin of cells with molecular precision [16,28].
Mammalian fate-mapping studies have adopted the LoxP/Cre
recombinase system. A mouse is constructed where a reporter
molecule such as green or red ﬂuorescent protein (GFP or RFP)
is inserted in the genome. This reporter gene is silencedwith an
upstream stop codon that is ﬂanked by LoxP sites (ﬂoxed) [16].
When this mouse is mated with a mouse that has a tissue-
speciﬁc promoter driving Cre recombinase, the stop codon in
that tissue is permanently removed, allowing for permanent
expression of the reporter. The label is driven by a strong,
constitutively active promoter. Therefore, all descendent cells
will express this reporter molecule. Moreover, this system can
be modiﬁed to generate inducible reporter expression or tis-
sue-speciﬁc reporter [16]. For example, in the kidney, podo-
cyte-speciﬁc gene expression can be achieved by crossing
reporter mice with a podocin promoterdCre gene construct.
Cre will be expressed in a tissue-speciﬁc manner, resulting in
permanent labeling of podocytes. This system can be manipu-
lated further by using an inducible promoter for the Cre gene.
That way, Cre can be turned on in a cell-speciﬁc manner by
adding an inducing agent, such as tamoxifen for an estrogen
receptoreinducible promoter [16].
Peritoneal mesothelial cells are somewhat more difﬁcult to
label as a speciﬁc marker is not available. The closest available
is a Wilms tumor-1 (WT1) promoter that labels mesothelial
cells and developing podocytes. Recent studies by Chen et al
[30] using this system will be outlined in the following
paragraphs.
Earlier work using lineage tracing came from models of
kidney injury and ﬁbrosis. Humphreys et al [22] used several
different kidney-speciﬁc promoter mice to demonstrate that
myoﬁbroblasts do not develop from injured tubular epithelial
cells in vivo; however, the in vitro response was similar to
earlier reported studies [17]. They did arrive at the surprising
result that the majority of interstitial myoﬁbroblasts actuallycame from perivascular cells within the interstitium after kid-
ney injury [22]. These striking results contradicted many pre-
vious studies, suggesting that EMT was a source of interstitial
myoﬁbroblasts after kidney injury.
Similar to Humphreys et al [22], LeBleu et al [57] also used
genetically modiﬁedmice to track the origin and function of the
myoﬁbroblast. Mice expressing yellow ﬂuorescent protein
driven by the a-SMA promoter mediated by the LoxP/Cre sys-
tem in a unilateral ureteric obstruction model of renal ﬁbrosis
exhibited an accumulation of a-SMAþ myoﬁbroblasts in the
interstitium of ﬁbrotic kidney [57]. Bone marrow transplant
experiments using a-SMA-RFP mice and immunolabeling for
a-SMAþ cells revealed that 35% of myoﬁbroblasts in the
interstitium of injured kidneys originated from the bone
marrow and 65% originated from resident cells including per-
icytes. Interestingly, ablation of bone marrowederived myoﬁ-
broblasts reduced kidney ﬁbrosis, whereas the deletion of
pericyte-derived myoﬁbroblasts did not [57]. Using mice
expressing yellow ﬂuorescent under the control of the g-glu-
tamyl transferase promoter (gGT) crossed with a-SMA-RFP
mouse, LeBleu et al [57] were able to demonstrate that a small
number (about 5%) of interstitial myoﬁbroblasts in the kidney
arose from epithelial cells through EMT.
Similar studies have been recently carried out by Chen et al
[30] in models of peritoneal ﬁbrosis. Transgenic mice were
generated to conditionally express red ﬂuorescent protein in
WT1þ cells. The WT1 promoter was conditionally induced
using tamoxifen to label mesothelial cells in adult mice. These
authors used several models of peritoneal membrane injury
including hypochlorite injection, exposure to dialysis ﬂuid, and
adenovirus-mediated gene transfer of TGF-b [30]. They
observed that WT1 labeled the majority of mesothelial cells
along with an occasional submesothelial cell of unknown type.
Following injury, very few WT1þ-RFP cells co-expressing
a-SMA were found in the thickened laminin scar. WT1þ-RFP
cells remained in the mesothelial layer. Type I collagen
(Col1A) reporter mice were used to label collagen-producing
cells in the peritoneum. a-SMA/Col1A-positive cells were found
in the interstitium as myoﬁbroblasts [30]. These were subse-
quently shown to originate from existing submesothelial ﬁ-
broblasts. Peritoneal mesothelial cells expressed Col1A after
injury, but not a-SMA, suggesting that the mesothelium par-
ticipates in the injury response, but not through EMT [30].
Because this study is one of the ﬁrst studies in the peritoneum
to directly contradict EMT as an origin of myoﬁbroblasts,
conﬁrmatory studies would be welcome. Furthermore, the
expression of WT1 in the submesothelium is not as speciﬁc a
cellular marker for mesothelium as kidney-speciﬁc markers.
The inducible WT1 promoter did not label all mesothelial cells
but did label a proportion (15%) of submesothelial ﬁbroblasts
[30]. The ﬁbroblast origin of myoﬁbroblasts in this study was
conﬁrmed using a double transgenic Col1A1 reporter mouse
with an inducible Col1A2 reporter construct. However, 65% of
submesothelial ﬁbroblasts were labeled with Col1A2, and these
expanded to become roughly 65% of all myoﬁbroblasts [30].
Therefore, the cell-speciﬁc markers in the peritoneum are
neither completely speciﬁc nor sensitive. This may have an
impact on the results obtained. Finally, in all these lineage-
tracing experiments, it is theoretically possible for the lineage
promoter to become transcriptionally silenced [28].
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ﬁbrosis?
Studies of myoﬁbroblasts in organ ﬁbrosis, including peri-
toneal ﬁbrosis, have focused on the origin of these cells in the
interstitial or submesothelial tissue. It is becoming increasingly
clear, however, that the injured epithelium may play a critical
role in directing organ repair without undergoing a full EMT
process with transition and migration to the interstitium.
Strong evidence for this comes from a recent article by Lovisa
et al [58] in evaluation of the role of the epithelium in directing
renal ﬁbrosis. These researchers developed a mouse model
where the key EMT transcription factors Twist or Snail were
silenced speciﬁcally in the renal tubular epithelium. In a model
of renal interstitial ﬁbrosis, they demonstrated that silencing
these transcription factors blocked the expression of a-SMA in
the renal tubular epithelium. By preventing EMT, or at least
cellular transition of epithelial cells, the extent of the renal
interstitial ﬁbrosis was abrogated [30].
In the work by Chen et al using a Col1A reporter mouse, the
injured mesothelial cells began to express collagen after peri-
toneal injury. They did not identify a-SMA staining of these
cells [30]. In our own models, we have seen several instances
where the peritoneal mesothelium undergoes a cellular tran-
sition and begins to express both cytokeratin and a-SMA,
without migration of these cells to the interstitium (in
situ EMT) [34] (Fig. 2C). Using laser capture microdissection,
injured peritoneal mesothelial cells expressed Snail, a-SMA,
and vascular endothelial growth factor, suggesting these cells
undergo EMT and elaborate growth factors that induce sub-
mesothelial resident cells to participate in the wound-healing
response [59]. The mesothelium is maintained in a healthy
balance by a combination of proﬁbrotic and antiﬁbrotic factors.
Among the antiﬁbrotic factors is bone morphogenic protein 7
which has been shown to be antagonized by the secreted factor
Gremlin [60]. Recently, we overexpressed Gremlin in the peri-
toneum, which led to in situ EMT. This cellular transition alone
was able to drive the subsequent peritoneal ﬁbrogenic response
with matrix deposition and angiogenesis [56].
Therefore, recent evidence concerning the origin of myoﬁ-
broblasts in organ ﬁbrosis using cell fateetracing experiments
may not be as contradictory with previous research as initially
thought. Our previous work is consistent with the possibility
that few of the myoﬁbroblasts in the interstitial tissue are
derived from the overlying epithelium. Despite this, there is
increasing evidence that injured epithelial cells undergo a
limited transition, or in situ EMT, and this may be sufﬁcient to
direct the subsequent interstitial or submesothelial ﬁbrosis.
Summary
The origin of the myoﬁbroblast requires further research as
the recent evidence from fate-mapping studies contradicts
evidence from the past [22,30]. This could be attributed to
technical difference between techniques and studies, or it could
be related to the development of the disease process and timing
of pathogenesis. Research from in vitro studies of the origin of
the myoﬁbroblast has been useful in identifying surrogate
markers of EMT including the loss of epithelial markers,
E-cadherin, and cytokeratin and gain of mesenchymal markers,
a-SMA, and Snail. Using these surrogate markers, several ani-
mal models of peritoneal membrane injury have providedevidence in support of EMT as a source of myoﬁbroblasts [55].
Most commonly used, immunoﬂuorescence methods have
identiﬁed the transitioning cells in vivo by analyzing co-
localization of epithelial and mesenchymal markers [28].
Moreover, most studies in vitro and in vivo support the injured
mesothelial cell as the progenitor of the myoﬁbroblast, and
there is one recent study with opposing results [30]. Studies of
ﬁbrosis in other organs also present evidence in support of EMT
[27]. Recently some studies of renal ﬁbrosis present results
opposing epithelia as a major source of the myoﬁbroblast but
still suggest that a smaller portion of cells derive from EMT [17].
Therefore, conﬁrmatory studies are necessary to further un-
derstand this process and to understand to what extent EMT is
contributing to the myoﬁbroblast population. This may be
explained by the concept of in situ EMT. In other words, injured
epithelial cells may not fully transition to yield a complete EMT,
and cells may only transition to an intermediate stage. A more
speciﬁc method is required to deﬁne and identify EMT as well
as account for the disease model that is being used to truly
understand its contribution to the origin of the myoﬁbroblast.
In the end, this may require using a combination of lineage-
tracing studies and EMT criteria. The role of in situ EMT in
driving peritoneal ﬁbrosis could be further evaluated by de-
leting key EMT transcription factors, such as Snail or Twist, in
the mesothelium in a model of peritoneal ﬁbrosis. Elucidating
the origin of myoﬁbroblast and better deﬁning the role of the
mesothelium will lead to development of new antiﬁbrotic
therapies and improvement of current treatment methods.Conﬂicts of interest
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